🚀 Tesla ending Model S and X

In partnership with

Market Overview
Read time 1.4 minutes

Year To Date Performances:

1. Tesla is officially closing the chapter on its premium legacy as CEO Elon Musk announced an "honourable discharge" for the Model S and Model X, with production slated to end in the second quarter of 2026. This tectonic shift marks Tesla's aggressive transition from a traditional automaker into a dedicated AI and robotics firm, as the company plans to gut the existing lines at its Fremont factory to make way for a massive production facility capable of churning out one million Optimus humanoid robots annually. Despite reporting its first annual revenue decline on record—hitting $94.8 billion for 2025—Musk is doubling down on a "pre-revenue" future by forecasting a staggering $20 billion in capital expenditures for 2026. With the Model 3 and Model Y now handling 97% of vehicle volume and the Cybercab autonomous taxi preparing for an April launch, the sunsetting of the luxury S and X models signals that Musk is no longer interested in building cars for humans to drive, but is instead betting the entire company's valuation on a fleet of bipedal robots and a fully subscription-based Full Self-Driving ecosystem.

2. Norway’s $2.2 trillion sovereign wealth fund has just reported a jaw-dropping record performance for 2025, fueled by a perfect storm of tech dominance and a massive resurgence in the global banking and mining sectors. Managed by Norges Bank Investment Management (NBIM), the fund effectively harnessed the "AI super-cycle" with heavy-hitting stakes in Nvidia, Apple, and Microsoft, while simultaneously reaping the rewards of a European banking renaissance and a literal silver lining in basic materials. The standout performer in their portfolio was the mining giant Fresnillo, which surged more than 452% to become the fund's basic materials crown jewel during a period of intense silver speculation and strategic acquisitions. While the provided headline mentions a $1.4 billion return, the underlying financial data of 13.4 trillion kroner actually indicates a return closer to $1.4 trillion USD, making this the most successful year in the fund’s history and solidifying its role as the world’s most influential institutional stabilizer.

3. The pharmaceutical landscape is currently witnessing a calculated "calm before the storm" as Roche and Sanofi meet analyst expectations without delivering the explosive growth that usually gets Wall Street's pulse racing. Roche is aggressively pivoting toward the lucrative obesity market, touting its CT-388 weight-loss candidate, which recently matched heavyweights like Wegovy in Phase 2 trials, while Sanofi is leaning on its immunology powerhouse, Dupixent, to maintain respectable 13% sales growth. Both CEOs are playing a high-stakes game of "beat the clock," attempting to replenish their pipelines with nearly 20 new medicines combined before the inevitable loss of patent protection turns their current blockbusters into generic commodities. While the €1 billion share buyback and high-single-digit 2026 forecasts offer a temporary safety net for investors, the real value of these companies now lies in their ability to turn experimental lab results into commercial juggernauts before the "patent cliff" arrives in earnest by the end of the decade.

   Headlines

   1. Mark Zuckerberg announced plans for Meta to increase its AI spending this year.

   2. India is predicting 7.2% growth for next year.